Post-SSRI Sexual Dysfunction (PSSD): What It Is and Whether It Goes Away

I’m a board-certified adult and forensic psychiatrist in North Carolina. More than once I’ve heard a version of the same account: a patient comes off an antidepressant, and the sexual side effects never lift. The desire doesn’t return, or the genitals feel oddly numb. When they raise it, they’re often told it must be the depression. Post-SSRI sexual dysfunction, or PSSD, is the clinical name for part of what they’re describing, and the evidence that it’s real has been building for more than a decade.

This piece is a companion to the practice’s guide on antidepressant discontinuation. Withdrawal and PSSD are different problems, and the difference matters for anyone trying to come off an SSRI safely.

What Post-SSRI Sexual Dysfunction Is

Sexual side effects during SSRI or SNRI treatment are common. Lowered libido, delayed orgasm, and blunted arousal affect a large share of people who take these drugs. In most cases the effects fade within days or weeks of stopping.

Sorting an on-treatment sexual side effect from low testosterone is its own question, one I take up in my guide to TRT and antidepressants.

PSSD is what happens when they don’t.

A 2021 consensus paper proposed formal diagnostic criteria for the condition (Healy et al., 2021). The core features are simple. The person took a serotonin reuptake inhibitor. After stopping, there’s an enduring change in genital sensation, often described as numbness, alongside reduced sexual desire or response. Sexual function was normal before the drug. And the problem is still present at least 3 months after the last dose.

That 3-month line is the part clinicians miss. Ordinary side effects can linger for a few weeks after discontinuation. Once the dysfunction outlasts three months, with the genital sensory change as its signature, PSSD becomes the more likely explanation.

The condition also sits within a family of related syndromes. The same lasting pattern shows up after stopping finasteride and after isotretinoin for acne, and a mirror-image presentation, persistent genital arousal disorder, can follow SSRIs as well. What ties them together is symptoms that outlast the drug by months or longer.

Sertraline’s discontinuation course is covered in Zoloft withdrawal.

PSSD sits alongside other persistent post-discontinuation problems; for the wider picture, see post-acute withdrawal syndrome.

What the Symptoms Look Like

The hallmark is a change in genital sensation. Some people describe reduced tactile feeling, as if the area had been numbed (Bala et al., 2018). Others describe a loss of erogenous sensation, where touch registers but carries no sexual charge (Healy et al., 2021).

Around that core, the picture varies. Orgasm can become muted, delayed, or pleasureless. Libido can drop sharply or disappear. Men may notice erectile difficulty or changes in ejaculation. Many patients also report emotional blunting, a flatness that runs alongside the physical numbness (Healy et al., 2021).

Severity covers a wide range. Some people have a partial, frustrating version. Others describe near-total genital anesthesia that has lasted years. The criteria set no upper limit on duration, because cases have been reported persisting more than a decade after the drug was stopped.

PSSD is not the only syndrome that can outlast a taper. Persistent brain zaps have been documented alongside PSSD in the same patient, which is one reason these post-stop syndromes are worth understanding together.

How Regulators Came to Recognize It

For years PSSD lived in patient forums and a handful of case reports. That changed when drug regulators looked at the signal.

In 2019 the European Medicines Agency reviewed the evidence and concluded that sexual dysfunction from SSRIs and SNRIs, which usually resolves after treatment stops, can be long-lasting in some patients even after withdrawal. The agency required a class-wide update to product information across these drugs, noting reports of sexual dysfunction continuing despite discontinuation (European Medicines Agency, 2019).

Health Canada followed in 2021. Its safety review reached an honest middle position: the evidence could not confirm or rule out a causal link. Even so, the agency moved to update the warnings section of Canadian product monographs for all SSRIs and SNRIs, advising clinicians to tell patients that sexual symptoms can last weeks to years after stopping (Health Canada, 2021).

SNRIs such as duloxetine are implicated too. If you’re coming off it, our guide to Cymbalta withdrawal covers the taper side.

The United States is the laggard. There’s no class-wide FDA action. The one place the warning appears is the fluoxetine (Prozac) label, which notes that symptoms of sexual dysfunction occasionally persist after discontinuation (FDA fluoxetine prescribing information). Every other SSRI label in the US is silent on it. A patient on sertraline or escitalopram won’t find the risk written anywhere in their prescribing information.

Paroxetine carries one of the higher sexual side-effect rates and is also the hardest SSRI to stop. See our guide on how to taper off paroxetine.

Why the Mechanism Is Still Unknown

Here’s where honesty matters. Nobody has proven what causes PSSD.

A 2022 review in Sexual Medicine Reviews set out the candidate mechanisms (Peleg et al., 2022). Long-term changes in serotonin signaling. Downstream effects on dopamine and on sex hormones. Epigenetic changes that outlast the drug. Damage to small nerve fibers in the genital tissue itself. Each hypothesis has some support, and none has been confirmed.

There’s no biomarker and no lab test. PSSD is diagnosed clinically, by matching the pattern and ruling out other causes. That uncertainty is uncomfortable, and it’s also the current state of the science. Any clinician who claims to know exactly why PSSD happens is ahead of the evidence.

How Common Is It

The truthful answer is that nobody knows the real rate.

A 2024 paper argued that incidence and prevalence can’t be pinned down yet, because the condition is under-recognized and goes badly under-reported. The same paper notes that PSSD has been given a code in MedDRA, the medical dictionary used for side-effect reporting, but that regulators didn’t appear to have adopted it as of 2024 (Healy and Mangin, 2024). People don’t volunteer genital numbness to a busy prescriber, and prescribers don’t ask.

One 2024 survey did put a number on a related symptom. Among past antidepressant users in the sample, 13.2% reported persistent genital numbness after stopping, compared with under 1% of people who’d used other medications (Pirani et al., 2024). That’s a striking association. It’s worth reading carefully, though, because the sample was sexual and gender minority youth aged 15 to 29 in the US and Canada rather than the general population, so the figure points to a strong link, not a population-wide rate.

Taken together, the evidence runs one direction. PSSD is real, almost certainly under-counted, and its exact frequency is still an open question.

Ruling Out the Treatable Causes First

Because there’s no test for PSSD, the diagnosis is partly a process of exclusion. That exclusion is where the real value sits, because several of the conditions that can mimic PSSD are treatable.

Low testosterone produces low libido, low energy, and erectile problems, and it’s easy to check. The practice covers this in its work on testosterone and mood and on hormones and mental health. Thyroid dysfunction can blunt desire. Vascular and neurological conditions can affect arousal and sensation. Another medication can turn out to be the real culprit.

Residual depression deserves its own line. Low libido and emotional flatness are also symptoms of a depression that hasn’t fully responded to treatment, which is exactly why the complaint so often gets waved off as “just the depression.” Separating genuine PSSD from an under-treated mood disorder, or from the anxiety that frequently travels with it, is a clinical judgment that takes time and a careful history.

When the depression underneath turns out to be the bigger problem, that’s its own work. My guide to depression treatment in North Carolina covers how a full evaluation separates the mood disorder from the medication effect.

If you’re weighing all of this while still on a medication, don’t stop it on your own. Abrupt discontinuation carries its own risks, which is the whole subject of the discontinuation guide. You can book an evaluation if you want that worked through properly.

Withdrawal is worst with short-half-life antidepressants. If you’re coming off one, our guide to venlafaxine withdrawal explains why Effexor is the hardest.

What Honest Care Looks Like in North Carolina

Two things define responsible care here, and neither one is a cure.

The first is informed consent before the prescription. The chance of persistent sexual side effects, small as the absolute number may be, belongs in the conversation before someone starts an SSRI, not after they’re stuck with it. Most patients have never been told it’s possible. They deserve to be.

The second is taking the symptom seriously when it appears. That means a real workup in place of a reflexive “it’s the depression,” ruling out the treatable contributors above, and being straight about what comes next. There’s no approved treatment for PSSD. A range of off-label approaches have been tried, and none has shown reliable, repeatable benefit. Anyone promising to fix PSSD is selling something the evidence doesn’t support.

What a practice can offer is an honest assessment, treatment of anything contributing that can be treated, careful decisions about any future medication, and a clinician who believes the patient and follows the science as it develops. Baghel Psychiatry works with patients across North Carolina by telehealth on exactly those terms.

Frequently Asked Questions

Is post-SSRI sexual dysfunction real?

Yes. Drug regulators in Europe (2019) and Canada (2021) reviewed the evidence and updated product information for SSRIs and SNRIs to acknowledge that sexual dysfunction can persist after the drug is stopped. The US fluoxetine label says the same. The mechanism isn’t understood, but the phenomenon is recognized in regulatory and clinical literature.

Does PSSD go away?

It varies, and there’s no way to predict it for an individual. Some people improve over months. Others have symptoms that have lasted years, and published cases describe persistence beyond a decade. No treatment has been shown to reliably reverse it, which is why honest expectation-setting matters.

How is PSSD diagnosed?

Clinically, using the proposed criteria and by excluding other causes. The pattern is an enduring change in genital sensation plus reduced desire or response, present at least three months after stopping a serotonin reuptake inhibitor, in someone whose sexual function was normal beforehand. There’s no blood test or scan for it yet, so ruling out hormonal, thyroid, vascular, and mood-related causes is part of the process.

Is there a treatment for PSSD?

There’s no approved treatment and no approach with proven, repeatable benefit. Various off-label options have been tried with inconsistent results. What good care can do is identify and treat any contributing condition that is treatable, manage the broader picture, and avoid making things worse. Be cautious of anyone who guarantees a cure.

Should I stop my antidepressant because of this risk?

Not on your own. For most people the medication is doing important work, and stopping abruptly carries real risks of its own. If you’re concerned about sexual side effects, raise it with your prescriber so the decision can be made deliberately and any taper supervised. The practice’s guide on antidepressant discontinuation explains why the way you come off matters.

This article is for educational purposes and is not medical advice. It does not establish a clinician-patient relationship. Post-SSRI sexual dysfunction is an area of active research with no approved treatment; nothing here should be read as a promise of any specific outcome. Do not start or stop any medication without speaking to your own prescriber. If you take an antidepressant, do not discontinue it abruptly.

References

1. European Medicines Agency. New product information wording, extracts from PRAC recommendations on signals (13-16 May 2019 PRAC; published 11 June 2019). EMA PRAC recommendation (PDF).
2. Health Canada. Summary Safety Review: SSRIs and SNRIs, assessing the potential risk of sexual dysfunction despite treatment discontinuation (2021). Health Canada Summary Safety Review SSR00254.
3. US Food and Drug Administration. PROZAC (fluoxetine) prescribing information. FDA label (PDF).
4. Healy D, Bahrick A, Bak M, Barbato A, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76. Epub 2021 Oct 26. PMID 34719438.
5. Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI Sexual Dysfunction: A Literature Review. Sex Med Rev. 2018;6(1):29-34. PMID 28778697.
6. Peleg LC, Rabinovitch D, Lavie Y, Rabbie DM, Horowitz I, Fruchter E, Gruenwald I. Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors. Sex Med Rev. 2022;10(1):91-98. PMID 34627736.
7. Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci. 2024;33:e40. PMID 39289881.
8. Pirani Y, Delgado-Ron JA, Marinho P, Gupta A, Grey E, Watt S, MacKinnon KR, Salway T. Frequency of self-reported persistent post-treatment genital hypoesthesia among past antidepressant users: a cross-sectional survey of sexual and gender minority youth in Canada and the US. Soc Psychiatry Psychiatr Epidemiol. 2025;60(7):1771-1779. Epub 2024 Sep 20. PMID 39302425.